Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will cover key topics of interest to stakeholders who set practice policy and will be called upon to evaluate and make decisions on issues pertaining to biosimilars.
Choose from the criteria below to find an activity that fits you best.
Tuesday, October 24, 2017, 11:00am - 12:00pm CT
(12pm ET/10am MT/9am PT)
With the advent of new agents for Atopic Dermatitis (AD) moving through specialty pharmacy channels, specialty pharmacists are suddenly at the hub of stakeholders in the treatment of AD. This activity will provide an overview of AD, including an introduction to the impact of inadequately treated moderate-to-severe disease and details of current and emerging therapies. The ways in which specialty pharmacists can work as part of multidisciplinary AD teams, actively engage in shared decision-making with patients, and reduce treatment barriers to increase value will be highlighted.
The target audience for this activity is pharmacists interested in or practicing in Specialty Pharmacy. After completing the activity, participants should be able to:
Speaker: Steven A. Scott, Pharm.D.
Department of Pharmacy Practice
Purdue University College of Pharmacy
West Lafayette, Indiana
Moderator: Laura Jester, PharmD
Pharmacist, PBM Specialty Pharmacy Programs
Navitus Health Solutions
ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-17-347-L01-P has been assigned to this live knowledge-based activity (initial release date 9-20-2017). This activity is approved for 1.0 contact hour (0.10 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. Statements of completion will be issued online at www.ProCE.com and proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and
scientific rigor in all of its continuing education activities. Faculty must disclose
to participants any significant financial interest or affiliation with companies that
manufacture or market products discussed during their presentation. Dr. Scott has
no relevant commercial or financial relationships to disclose. Dr. Jester has no relevant
commercial or financial relationships to disclose. A portion of grant funds received
by ProCE from Sanofi Genzyme and Regeneron Pharmaceuticals will be used to compensate
the faculty for this presentation.
Please note: The opinions expressed in this activity should not be construed as those of the CE provider. The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.
This CE activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.